Clinical characteristics | Patients (n = 25) | Progressive disease (n = 9) | Non-progressive disease (n = 15) | p values |
---|---|---|---|---|
Age (years, mean ± SD) | 69 ± 8 | 67 ± 9 | 70 ± 8 | NS |
Gender | ||||
Male % (n) | 68 (17) | 67 (6) | 67 (10) | NS |
Female % (n) | 32 (8) | 33 (3) | 33 (5) | NS |
Tabagism | ||||
Non-smoker % (n) | 12 (3) | 11 (1) | 13 (2) | NS |
Active smokers % (n) | 0 (0) | 0 (0) | 0 | NS |
past smokers % (n) | 80 (20) | 78 (7) | 80 (12) | NS |
Passive smoker % (n) | 8 (2) | 11 (1) | 7 (1) | NS |
Anti-fibrotic treatment | ||||
Pirfénidone % (n) | 56 (14) | 67 (6) | 46 (7) | NS |
Nintedanib % (n) | 44 (11) | 33 (3) | 54 (8) | NS |
Pulmonary function tests | ||||
FVC (l, mean +/− SD) | 2,4 ± 0,8 | 2,2 ± 0,8 | 2,5 ± 0,7 | NS |
FVC (%, mean +/− SD | 73,7 ± 20,2 | 63,6 ± 17,2 | 78,9 ± 20,6 | NS |
DLCO (ml/min/mmHg, mean +/− SD) | 10,5 ± 3,5 | 9,3 ± 3,4 | 11,1 ± 3,4 | NS |
DLCO (%, mean +/− SD) | 43,5 ± 12,0 | 38,3 ± 11,3 | 46,8 ± 11,5 | NS |
GAP score (n): | ||||
Stage 1% (n) | 28 (7) | 11 (1) | 40 (6) | NS |
Stage 2% (n) | 56 (14) | 67 (6) | 47 (7) | NS |
Stage 3% (n) | 16 (4) | 22 (2) | 13 (2) | NS |